Can chewing gum lower HPV levels? What a new study found
Human papillomavirus (HPV) is best known as the leading cause of cervical cancer, but it also drives a growing share of head and neck cancers, particularly oropharyngeal cancers. Researchers have long sought ways to reduce oral HPV viral load, and a new study suggests a simple chewing gum might help.
The study used a specially formulated gum containing specific plant-derived compounds and binding proteins. Researchers hypothesized that these compounds could physically bind to virus particles in the mouth, helping clear them from the body.
In the trial, participants who tested positive for oral HPV chewed the gum at regular intervals over several weeks. Researchers collected saliva samples before and after the study period to measure changes in viral load.
The results showed a marked reduction in viral load among a substantial share of participants, with the decrease reaching as high as 93% in some cases. Researchers note the effect varied among individuals, but the overall trend was consistent.
Scientists say the findings carry particular significance because no approved method currently treats oral HPV infection directly. Existing approaches rely largely on vaccination for prevention and regular screening.
Researchers explain the gum is not expected to replace vaccination, but could instead serve as a complementary tool — reducing viral load in people already infected, potentially lowering transmission risk and the likelihood of eventual cancer development.
One of the study's most notable aspects is the gum's low cost and easy accessibility. Experts say that if efficacy is confirmed in larger trials, the approach could become an important public health tool, particularly in regions where access to healthcare remains limited.
On safety, researchers say the compounds used meet food safety standards and no serious adverse effects were reported during the study. However, the effects of long-term use have not yet been investigated.
Independent experts urge cautious optimism given the small sample size, stressing that larger, randomized controlled trials are needed to confirm the results.
The research team says the next stage will involve a larger, multi-site study with broader participant groups, expected to clarify both the gum's efficacy and whether it reduces the risk of head and neck cancer.
Read next
The moment an earthquake shook a Japanese hospital mid-operation, and what it reveals about disaster-ready care
Security camera footage from Kumamoto General Hospital shows surgeons shielding a patient on the operating table as a magnitude 6.8 earthquake shook the building last month. The video has renewed attention on how hospitals in seismically active regions design operating rooms, staff protocols and building infrastructure to keep surgery safe during a disaster.
FDA approves Bristol Myers Squibb drug, marking debut of a new class for blood cancer
The US Food and Drug Administration has approved a Bristol Myers Squibb treatment, marketed as Zenbexus, for advanced multiple myeloma, introducing a new class of drugs for the incurable blood cancer. The approval offers another option for patients whose disease has stopped responding to existing therapies.
Can antihistamines really ease PMDD and menopause symptoms
A social media trend claims that combining two over-the-counter antihistamines, Allegra and Pepcid, can dramatically ease the emotional and physical symptoms of premenstrual dysphoric disorder and menopause. Doctors say there is a plausible biological mechanism involving mast cells and hormones, but caution that the evidence remains thin and self-medicating carries real risks.
Iceberg, romaine or kale: which salad greens are actually the healthiest
Nutritionists say not all salad greens are created equal: darker, more bitter leaves generally carry more vitamins, minerals and fiber than pale, watery ones like iceberg lettuce. Here is how the most common options compare, and what actually matters when building a healthy salad.
Triple-drug treatment clears HIV in newborn primates within days of exposure
Researchers used a one-time combination of three therapies — standard antiretrovirals, broadly neutralizing antibodies and an experimental antibody — to completely clear HIV from newborn nonhuman primates treated within three days of exposure. None of the three treatments cleared the virus alone, suggesting a narrow but real window for eliminating infection soon after birth.